Patents by Inventor Lars-Olof Lindquist

Lars-Olof Lindquist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6835379
    Abstract: A method for producing IgG from plasma for medical applications, comprising at least: (i′) removal of albumin resulting in an IgG fraction, (ii′) purifying IgG from an IgG fraction, which is derived from the IgG fraction obtained in step (i′), by adsorbing IgG to a cation exchanger and collecting the adsorbed IgG fraction, and (iii′) virus inactivation in an IgG fraction derived from the IgG fraction collected in step (ii′). The method is characterized in; (I) concentrating the IgG fraction obtained in step (i′), (II) adjusting pH to 4±0.1 in the IgG fraction released from the cation exchanger in step (ii′), and preferably maintaining the pH below 6.0 during the remaining steps of the method; and (III) carrying out the virus inactivation (step iii′) by using chemicals at a temperature of 30° C.±2° C. for at least 4 hours. Anticomplementary activity is typically below 1 CH50/mg immunoglobulin.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: December 28, 2004
    Assignee: Amersham Biosciences AB
    Inventors: Inger Andersson, Lars-Olof Lindquist
  • Publication number: 20030143222
    Abstract: A method for producing IgG from plasma for medical applications, comprising at least: (i′) removal of albumin resulting in an IgG fraction, (ii′) purifying IgG from an IgG fraction, which is derived from the IgG fraction obtained in step (i′), by adsorbing IgG to a cation exchanger and collecting the adsorbed IgG fraction, and (iii′) virus inactivation in an IgG fraction derived from the IgG fraction collected in step (ii′). The method is characterized in; (I) concentrating the IgG fraction obtained in step (i′), (II) adjusting pH to 4±0.1 in the IgG fraction released from the cation exchanger in step (ii′), and preferably maintaining the pH below 6.0 during the remaining steps of the method; and (III) carrying out the virus inactivation (step iii′) by using chemicals at a temperature of 30° C.±2° C. for at least 4 hours. Anticomplementary activity is typically below 1 CH50/mg immunoglobulin.
    Type: Application
    Filed: December 9, 2002
    Publication date: July 31, 2003
    Inventors: Inger Andersson, Lars-Olof Lindquist